XML 101 R94.htm IDEA: XBRL DOCUMENT
v3.25.2

Share-based payments - Schedule of Share Based Assumptions (Details) € / shares in Units, € in Thousands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 23, 2024 € / shares | Jul. 20, 2023 € / shares | Jun. 22, 2022 EUR (€) yr € / shares | Jun. 21, 2021 EUR (€) yr € / shares | Apr. 20, 2021 EUR (€) yr € / shares | Mar. 17, 2020 € / shares | Mar. 11, 2020 € / shares | Mar. 29, 2019 € / shares | Jul. 27, 2018 € / shares | Mar. 06, 2018 € / shares | Jan. 07, 2017 yr € / shares | Nov. 03, 2016 € / shares | Feb. 02, 2016 € / shares | Jun. 25, 2015 € / shares | Jun. 10, 2015 € / shares | Feb. 10, 2015 € / shares | Jun. 30, 2025 EUR (€) yr € / shares | Jun. 30, 2024 EUR (€)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2,161 | € 1,940
BSPCE |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0
BSPCE 2015-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 18.57 |  |
BSPCE 2015-3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 20.28 |  |  |
BSPCE 2016 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  | € 14.46 |  |  |  |  |
BSPCE 2016 P |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  | 14.46 |  |  |  |  |
BSPCE 2017 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  | € 15.93 |  |  |  |  |  |  |
BSCPE 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  | 15.93 |  |  |  |  |  |  |
BSA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0
BSA 2015-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 17.67 |  |
BSA 2015-2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  | € 19.54 |  |  |  |
BSA 2018-2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  | € 16.10 |  |  |  |  |  |  |  |  |
BSA 2019-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  | € 11.66 |  |  |  |  |  |  |  |  |  |
BSA 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  | € 6.59 |  |  |  |  |  |  |  |  |  |  |  |
OSA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,273 | 708
OSA 2016-1 P |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  | € 13.05 |  |  |  |  |
OSA 2016-2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  | € 14.26 |  |  |  |  |  |
OSA 2017 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  |  | € 14.97 |  |  |  |  |  |  |
OSA 2017 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 5.5 |  |  |  |  |  |  |
OSA 2017 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |
OSA 2017 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 6.5 |  |  |  |  |  |  |
OSA 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  |  |  | € 12.87 |  |  |  |  |  |  |  |
OSA 2019-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  |  | € 11.08 |  |  |  |  |  |  |  |  |  |
OSA 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  |  |  | € 6.25 |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  |  | € 684 |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | (4)
Share price (in euros per share) |  |  |  |  | € 13.60 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  | € 13.74 |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  | 5.5 |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  | 6.5 |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  | 38.90% |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  |  | 0.38% |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  | 37.80% |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  |  | 0.33% |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  | 38.30% |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  |  | 0.28% |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-04 P |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  |  | € 1,816 |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 48 | 77
Share price (in euros per share) |  |  |  |  | € 13.60 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  |  | € 13.74 |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  | 39.10% |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  |  | 0.03% |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  | € 246 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13
Share price (in euros per share) |  |  |  | € 12.20 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  | € 12.99 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  | 5.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  | 6.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  | 39.20% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  | 0.35% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  | 37.90% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  | 0.30% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  | 38.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  | 0.26% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2021-06 P |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  | € 212 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 | 12
Share price (in euros per share) |  |  |  | € 12.20 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  |  | € 12.99 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  | 39.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  |  | 0.13% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 P |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  | € 71 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 2
Share price (in euros per share) |  |  | € 3.68 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  | € 4.16 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 40.08% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 2.28% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  | € 580 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 23 | 57
Share price (in euros per share) |  |  | € 3.68 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  |  | € 4.16 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  | 5.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  | 6.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 42.06% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 1.83% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 41.21% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 1.87% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2022-06 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 40.65% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 1.90% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2023-01 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  | € 1,255 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 164 | 357
Share price (in euros per share) |  |  |  | € 6.75 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) |  | € 5.00 |  | € 5.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2023-01 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 45.07% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 2.85% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2023-01 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 44.11% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 2.83% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2023-01 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 43.41% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 2.82% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2024-01 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  | € 3,107 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 837 | 194
Share price (in euros per share) |  |  |  | € 5.19 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € 5.81 |  |  | € 5.81 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2024-01 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 5.4 |  |  |  |  |  |  |
OSA 2024-01 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 5.9 |  |  |  |  |  |  |
OSA 2024-01 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  | 6.4 |  |  |  |  |  |  |
OSA 2024-01 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 53.30% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2024-01 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 51.90% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.02% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2024-01 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  | 50.70% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.02% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OSA 2025-01 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 3 | 0
Share price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 3.65 |
Exercise price (in euros per share) |  | € 3.36 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 3.36 |
Yield |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.00% |
OSA 2025-01 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.18% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.4 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.83% |
OSA 2025-01 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.43% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.9 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.91% |
OSA 2025-01 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.57% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.4 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.98% |
OSA 2025-02 O |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2,523 |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 186 | 0
Share price (in euros per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 3.74 |
Exercise price (in euros per share) | € 2.97 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2.97 |
Yield |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.00% |
OSA 2025-02 O | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.56% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.4 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.53% |
OSA 2025-02 O | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.32% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.9 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.61% |
OSA 2025-02 O | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47.43% |
Maturity (in years) | yr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.4 |
Risk-free rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.70% |
AGA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 888 | 1,232
AGA 2023 - P1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price (in euros per share) |  |  | € 4.87 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euro per share) |  |  | € 0.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  | € 2,071 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 446 | 472
AGA 2023 - P1 | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AGA 2023 - P1 | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.20% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AGA 2023 - P2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price (in euros per share) |  |  | € 4.87 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euro per share) |  |  | € 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Yield |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of initial plan | € |  |  | € 2,130 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for the year | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 442 | € 507
AGA 2023 - P2 | Tranche one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AGA 2023 - P2 | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free rate |  |  | 3.20% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The option life of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DescriptionOfOptionLifeShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The exercise price of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ExercisePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of an expected dividend used to calculate the fair value of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 51 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding + References No definition available. + Details
Name: | nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems
Namespace Prefix: | nbx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise Price, Other Equity Instruments Granted + References No definition available. + Details
Name: | nbx_ExercisePriceOtherEquityInstrumentsGranted
Namespace Prefix: | nbx_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected Dividend As Percentage, Other Equity Instruments Granted + References No definition available. + Details
Name: | nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
Namespace Prefix: | nbx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk Free Interest Rate, Other Equity Instruments Granted + References No definition available. + Details
Name: | nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted
Namespace Prefix: | nbx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan + References No definition available. + Details
Name: | nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Weighted Average Share Price, Other Equity Instruments Granted + References No definition available. + Details
Name: | nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted
Namespace Prefix: | nbx_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_VestingPeriodAxis=nbx_TrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_VestingPeriodAxis=nbx_TrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_VestingPeriodAxis=nbx_TrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202206OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202301OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202401OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202501OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202502OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Performance2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |